Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment.
from Reuters: Health News https://reut.rs/2UIq8Vr
via IFTTT
from Reuters: Health News https://reut.rs/2UIq8Vr
via IFTTT
Post a Comment